드라이 파우더 흡입기 : 세계 시장 인사이트, 경쟁 구도, 시장 예측(2030년)

Dry Powder Inhaler Devices Market By Product Type (Disposable, Capsule, And Blister), By Patient Type (Adult And Pedriatric), By Application (Chronic Obstructive Pulmonary Diseases (Copd), Asthma, Covid-19, Diabetes, And Others), By Type (Single-Use And Multi-Use), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of covid-19 and rising prevalence of diabetes

The global dry powder inhaler devices market was valued at USD 13,935 million in 2023, growing at a CAGR of 4.58% during the forecast period from 2024 to 2030 to reach USD 18,626 million by 2030. The dry powder inhaler devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings. Therefore, the market for dry powder inhaler devices is estimated to grow during the forecast period from 2024 to 2030.

Dry Powder Inhaler Devices Market Dynamics:

One of the main drivers of the dry powder inhaler devices market is the rising prevalence of diabetes. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2023, worldwide, diabetes affected roughly 537 million people of age between 20-79 years. By the year 2030, the overall number of diabetes is expected to reach 643 million, and by 2045, it will reach 783 million. Thus, dry powder inhaler are used to treat diabetes by using insulin powder. Therefore, rising diabetes cases increases the demand of dry powder inhaler devices, which drives the overall dry powder inhaler devices market forward over the forecast period (2024-2030).

Moreover, another key factor which is responsible for the growth of dry powder inhaler devices market is the increasing prevalence of asthma. For instance, according to World Health Organization (WHO) published data in the year 2023, asthma affected 262 million people in 2019 worldwide. Further, dry powder inhaler devices are used to deliver asthma medication to the lungs, thus increasing prevalence of asthma increases the demand for dry powder inhaler devices, which leads to a surge in the dry powder inhaler devices market during the forecast period.

However, lack of awareness about dry powder inhaler devices and disadvantages associated with the devices, can hamper the global dry powder inhaler devices market growth.

The COVID-19 pandemic has positively impacted the market for dry powder inhaler devices, this can be anticipated owing to the severe effects of COVID-19 on lungs and COVID-19 patients that had suffered with respiratory infections as an after effect of COVID-19, as well as shortness of breath as its prevalent symptom, had also contributed to the dry powder inhaler devices demand among COVID-19 patients. Hence, the demand for dry powder inhaler devices will continue to rise in the forecast period from 2024-2030.

Dry Powder Inhaler Devices Market Segment Analysis:

Dry Powder Inhaler Devices Market by Product Type (Disposable, Capsule and Blister), Patient Type (Adult and Pediatric), Application (Chronic Obstructive Pulmonary Diseases (COPD), Asthma, COVID-19, Diabetes, and Others), Type (Single-Use and Multi-Use), Distribution Channel (Online and Offline), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the by type segment of dry powder inhaler devices market, single use is expected to share a significant revenue in the year 2023. Single use dry powder inhalers devices are disposable, cost effective, minimize the risk of infections, offers a better approach to deliver medications than reusable ones and can assist a variety of needs. Thus, these benefits associated with the single use dry powder inhaler devices increases its demand, which leads to a surge in the dry powder inhaler devices overall market. However, increase in patents approvals associated with the dry powder inhaler devices also drives its market growth.

In February 2020, Hovione Technology, a Contract Development and Manufacturing Company, has reported that one of its big dosage dry powder inhaler (DPI) systems, the TwinMax DPI, has received patent approvals. TwinMax is a 2-puff disposable DPI that is developed for applications that need a high dosage administration to the lungs. It has a patent-pending architecture that allows it to deliver dosages up to 100 mg as medication alone or tailored particles.

Furthermore, such type of approvals and benefits associated with single-use dry powder inhaler devices, in the product type segment would result in the rising demand for dry powder inhaler devices which in turn would provide a conducive growth for the overall dry powder inhaler devices market during the forecast 2024-2030.

North America is expected to dominate the overall Dry Powder Inhaler Devices Market:

Among all the regions, North America is expected to dominate the global dry powder inhaler devices market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the rising prevalence of COVID-19 and surge in cystic fibrosis cases are expected to increase the demand of dry powder inhaler devices in the North American market.

According to the data published by WHO from 3 January 2020 to 21 September 2022, there have been 94,471,064 confirmed cases of COVID-19 in United States. Further, COVID-19 increased the respiratory infections in the patients affecting the lungs. Thus, rising prevalence of COVID increased the demand for dry powder inhaler devices, which surged the growth for dry powder inhaler devices overall market forecast.

Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per cystic fibrosis Canada's 2020 annual data report from the Canadian Cystic Fibrosis Registry, had released that in 2020, there were 4,332 Canadians with CF, with 62 percent of them being adults. Further, dry powder inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for dry powder inhaler devices, which boost the dry powder inhaler devices overall market growth.

Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in dry powder inhaler devices market.

Dry Powder Inhaler Devices Market Key Players:

Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, Otsuka Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Hofliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS, and among others.

Recent Developmental Activities in the Dry Powder Inhaler Devices:

In June 2022, Glenmark Pharmaceuticals Ltd, a research-driven global integrated pharmaceutical company, is one of the first to introduce a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) in the United Kingdom under the brand name Tiogiva® for the treatment of chronic obstructive pulmonary disease (COPD).

In May 2020, Iconovo, offers the development of inhalation products, has announced that the ICOcapTM dry powder inhaler, which is based on capsules, has received CE approval for use in clinical studies.

Key Takeaways from the Dry Powder Inhaler Devices Market Report Study

• Market size analysis for current dry powder inhaler devices market (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the dry powder inhaler devices market
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint venture happened over last 3 years
• Key companies dominating the global dry powder inhaler devices
• Various opportunities are available for the other competitor in the dry powder inhaler devices market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current dry powder inhaler devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for dry powder inhaler devices market growth in the coming future?

Target Audience who can be benefited from this Dry Powder Inhaler Devices Market Report Study

• Dry powder inhaler devices providers
• Research organizations and consulting companies
• Dry powder inhaler devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in dry powder inhaler devices
• Various end-users who want to know more about the dry powder inhaler devices market and latest technological developments in the dry powder inhaler devices

Frequently Asked Questions for Dry Powder Inhaler Devices:

1. What are Dry Powder Inhaler Devices?

A Dry-Powder Inhaler (DPI) is a device that uses dry powder to deliver medicine to the lungs. DPIs are often used to treat respiratory disorders such as asthma, bronchitis, emphysema, and COPD, but they have also been used to treat diabetes mellitus.

2. What is the market for Global Dry Powder Inhaler Devices?

The global dry powder inhaler devices market was valued at USD 13,935 million in 2023, growing at a CAGR of 4.58% during the forecast period from 2024 to 2030 to reach USD 18,626 million by 2030.

3. What are the drivers for the Global Dry Powder Inhaler Devices market?

The dry powder inhaler devices market is witnessing a positive market growth owing to the factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings.

4. Who are the key players operating in the Dry Powder Inhaler Devices market?

Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, Otsuka Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Hofliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS and among others.

5. Which region has the highest share in Dry Powder Inhaler Devices Market?

North America is expected to dominate the global Dry powder inhaler devices market. Factors contributing to the growth of dry powder inhaler devices market in the North America region are rising prevalence of COVID-19 and surge in cystic fibrosis cases.

Table of Contents

1.Dry Powder Inhaler Devices Market Report Introduction

2. Dry Powder Inhaler Devices Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The US
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Dry Powder Inhaler Devices Market Key Factors Analysis

• 4.1. Dry Powder Inhaler Devices Market Drivers
  • 4.1.1. Increasing Prevalence of Chronic Obstructive Pulmonary Diseases (COPD)
  • 4.1.2. Rising Prevalence of Diabetes
  • 4.1.3. Rising Prevalence of COVID-19
  • 4.1.4. Surge in Cystic Fibrosis Cases
• 4.2. Dry Powder Inhaler Devices Market Restraints And Challenges
  • 4.2.1. Lack of Awareness about Dry Powder Inhaler Devices
  • 4.2.2. Disadvantages Associated with the Devices
• 4.3. Dry Powder Inhaler Devices Market Opportunities
  • 4.3.1. Single-Use Dry Powder Inhalation Devices Could Be Influential in the Development of Future Vaccination Strategies
  • 4.3.2. Increasing Research and Development Activities in Dry Powder Inhaler Devices

5. Dry Powder Inhaler Devices Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Dry Powder Inhaler Devices Market

7. Dry Powder Inhaler Devices Market Layout

• 7.1. By Product Type
  • 7.1.1. Disposable
  • 7.1.2. Capsule
  • 7.1.3. Blister
• 7.2. By Patient Type
  • 7.2.1. Adult
  • 7.2.2. Pedriatric
• 7.3. By Application
  • 7.3.1. Chronic Obstructive Pulmonary Diseases (COPD)
  • 7.3.2. Asthma
  • 7.3.3. COVID-19
  • 7.3.4. Diabetes
  • 7.3.5. Bronchitis
  • 7.3.6. Others
• 7.4. By Type
  • 7.4.1. Single-Use
  • 7.4.2. Multi-Use
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.1.2. Canada Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.1.3. Mexico Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.2.2. Germany Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.2.4. Italy Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.2.5. Spain Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.2.6. Russia Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.2.7. Rest of Europe Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.3.2. Japan Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.3.3. India Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.3.4. Australia Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.3.5. South Korea Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia Pacific Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.4.2. Africa Dry Powder Inhaler Devices Market Size in USD million (2021-2030)
    • 7.5.4.3. South America Dry Powder Inhaler Devices Market Size in USD million (2021-2030)

8. Dry Powder Inhaler Devices market Global Company Share Analysis - Key 3-5 Companies

9. Dry Powder Inhaler Devices Market Company and Product Profiles

• 9.1. Boehringer Ingelheim Inc
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. CHIESI Farmaceutici S.p.A
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Cipla Inc
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. GSK Group of Companies
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Hovione
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. OPKO Health Inc
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Teva Pharmaceutical Industries Ltd
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Vectura Group Ltd
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Radius Innovation & Development
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Otsuka Pharmaceutical Co Ltd
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. RESPIRA THERAPEUTICS INC
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. MannKind Corporation
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Pharmaxis Ltd
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Stevanato Group
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Harro Hofliger Verpackungsmaschinen GmbH
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. H&T Presspart Manufacturing Ltd
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Catalent Inc
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Merxin Ltd
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Manta Devices LLC
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. PUREIMS
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us